Navigation Links
FDA Grants 510(k) Clearance to Curos® Disinfecting Port Protector
Date:1/18/2012

CARLSBAD, Calif., Jan. 18, 2012 /PRNewswire/ -- Ivera Medical Corporation today announced it has received a new FDA 510(k) clearance for its Curos® disinfecting port protector which reflects the company's ongoing determination to continuously improve its products to better deliver solutions designed to reduce hospital-acquired catheter related bloodstream infections. The Curos passive disinfection cap  first received 510(k) clearance in 2008. The new 510(k) clears Curos for improved performance claims including a reduction in disinfection time and an extension of the product's effective duration of use. Independent studies submitted to the FDA established that Curos caps disinfect IV access ports within three minutes and that ports remain clean for seven days without access.

With two dispenser options—the Curos Strip or individual Curos—nurses can conveniently comply with disinfection protocols for intravenous (IV) valves by simply peeling the foil seal off the distinctive green cap and twisting Curos over the top of any luer-activated IV access port or needleless valve. Inside Curos a 70% IPA (isopropyl alcohol) saturated sponge-like foam automatically provides effective, consistent and reliable passive disinfection of the port.

"In the battle to prevent bloodstream infections, the ease of use of a solution is critically important to its effectiveness. Curos is designed for minimal effort and maximum effect," said Bob Rogers, Ivera Medical's chief executive officer. "With a shorter time to disinfection and a longer duration of use, the patient's IV ports are verifiably clean and guaranteed to stay that way between accesses because the Curos design complies with the 2011 INS Standards of Practice which specifies the use of secure lock-locks on all "add-on" devices."

The Curos disinfecting port protector cap may be used in the home or healthcare facility and is intended for use on swab-able luer-activated IV valves to both disinfect and protect vulnerable points of entry to the patient's bloodstream. According to the new 510(k) clearance, Curos will disinfect the valve three minutes after application and act as a physical barrier to contamination for up to seven days if not removed. The effectiveness of Curos disinfecting port protectors were tested in vitro and found to provide effective disinfection of gram positive organisms (Staphylococcus aureus and Staphylococcus epidermidis), gram negative organisms (Escherichia coli and Pseudomonas aeruginosa) and fungi (Candida glabrata and Candida albicans.)

Curos disinfects needless IV connectors to help prevent catheter-related bloodstream infections (CRBSI) including central line associated bloodstream infections (CLABSI) and to reduce the incidence of contaminated blood cultures. In a six-month controlled study conducted by a university hospital Curos contributed to an 86.2 percent reduction in CLABSI and a 92 percent fall in contaminated blood cultures in a 12-bed bone marrow transplant unit and 20-bed oncology unit. Annualized cost avoidance (within the 32-bed study area) as a result of Curos use was estimated at $500,000.  Researchers concluded that the reduction in CLABSI rate and the efficacy of Curos, in part, is ascribed to the easily monitored disinfection compliance (greater than 85 percent on average.)

Although disinfection caps are a simple solution for hospital infection prevention — an alcohol-soaked foam inside a small plastic screw cap — much thought and ingenuity were required to develop it. Curos technology is designed to integrate smoothly with clinical practice, support port protection compliance and avoid waste in product use and disposal.

"We carefully engineered every detail of Curos to be more safe and effective. Even the distinctive green color was chosen specifically to allow clinicians to verify that a port is clean — at a glance — without creating confusion among other colors which imply specific therapies such as enteral tubes. We've created dispensing methods that put Curos in reach when and where nurses need them and limit the packaging waste to the bare minimum," stated Rogers. "A key component in the fight against hospital-acquired bloodstream infections is the ability to put validated tools into the hands of caregivers. The FDA's 510(k) clearance of Curos is a pivotal step in that direction, and reinforces Ivera's commitment to providing higher-quality and innovative solutions to our customers."

About Ivera Medical (www.iveramed.com)

Ivera Medical, headquartered in Carlsbad CA, developed and markets Curos disinfecting port protectors, the first disinfecting cap to be marketed in the US. Ivera's mission is to provide technologies and support services that help healthcare providers reduce the incidence of preventable bloodstream infections.  Hospital-acquired infections are estimated to cause or contribute to over 99,000 deaths annually, and to add nearly $6 billion each year to the cost of health care.     

Contact:
Bob Rogers
Chief Executive Officer
Ivera Medical Corp.
Bob.rogers@iveramed.com
760-612-6090


'/>"/>
SOURCE Ivera Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2. US Patent Office Grants COPAN Invention of Flocked Swabs
3. The European Commission Grants Marketing Authorization for DIFICLIR™ (fidaxomicin) Tablets for Treatment of Clostridium difficile Infections
4. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
5. FDA Awards NIPTE Potential $35 Million in Grants to Reform Drug Manufacturing Process
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Pevion Grants CSL Option Right to its Therapeutic Candida Vaccine
8. Muscular Dystrophy Association Awards $13.7 Million for 40 New Research Grants
9. FDA Grants Fast Track Designation to Bayers Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
10. Echo Therapeutics Announces Multiple Patents and Trademark Grants
11. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016  Eli Lilly and Company (NYSE: ... for 2017 and provide updated financial guidance for 2016 ... a conference call on that day with the investment ... guidance. The conference call will begin at ... can access a live webcast of the conference call ...
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific ... definitive agreement to acquire certain manufacturing assets and capabilities ... (TSX: NVC) advanced biological tissue business, as well as ... of $75 million in cash. The Neovasc advanced biological ... including the Boston Scientific Lotus™ Valve System. * ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will ... Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in the ... beyond the standard of care, demonstrating leadership within the MPN community and/or a commitment ...
(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... ... an inspirational interview of two ostomy patients, standing as living proof that attitude ... suffer from digestive diseases and issues that spike around the holidays. This campaign ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
Breaking Medicine News(10 mins):